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Identity 
Other names: MGC126241; MGC126242 
HGNC (Hugo): HAS2 
Location: 8q24.13 
Note 
HA Synthase 2 was first cloned in 1996 by Watanabe 
and Yamaguchi. The following year, Spicer et al. 




Three independently expressed hyaluronan synthase 
genes have been identified in the human genome. 
HAS2 is present in chromosome 8q24.12, while HAS1 
and HAS3 have been identified to loci 19q13.4 and 
16q22.1 respectively. 
Description 
The HAS2 gene encodes for a 552 amino acid product 
comprised of 4 exons. Translation starts at the first 
nucleotide of exon 2 while a discrete 5'-untranslated 
region (UTR) is formed in exon 1. 
Transcription 
Hyaluronan is catalyzed by three membrane- 
embedded HA synthases, although HAS2 is the only 
essential gene. The isozymes are coded by 3 separat 
genes that, although related, are unlinked in the 
chromosome. Regulation occurs at trans-cription, post-
translational levels, as well as, by alternative splicing, 
differential sub-cellular locali-zation and epigenetic 
processes. Hyaluronan deposits in the extracellular 
matrix have been associated with a variety of cellular 
processes such as motility, adhesion, division, 
morphogenesis, wound healing and vascular 
development. HAS2 overexpression, as well as, 
amplification of locus 8q24.12, has been implicated in 
tumor proliferation and metastasis in genitourinary 
tumors. Recently, the degree to which HA synthases 
can overexpressed has suggested the likelihood the 




HAS2, a member of the glycosyl transferase family 2 
proteins, is a multipass transmembrane protein that
catalyses the polymerization of the integral 
extrecellular matrix component Hyaluronic acid from 
intracellular UDP-esterified precursor, resul-ting in




HAS2 gene presented in the minus strand of chromosome 8. 
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Illustration of HAS multipass transmembrane isozymes and their products. 
 
Description 
HAS2 is one of the three characterized HA synthases 
responsible for the polymerization of Hyaluronic Acid 
in the extracellular matrix and is the only essential gene 
of the family. Although all three isozymes are equally 
capable of synthesizing HA polymers, it has been 
shown that HAS2 is the main HA synthase 
polymerizing long hyaluronan chains of MW ~2x106 
Daltons. 
Expression 
The extent of HAS2 expression and catalytic activity 
has been linked to specific interactions between the 
extracellular hyaluronan and the HA receptors, CD44 
and RHAMM, distributed in the plasma membrane. 
The underlying signaling pathways regulating HAS2 
expression have not been fully characterized. A number 
of distinctively regulated factors have been associated 
with HA deposition and HAS2 expression such as IL-
1beta, NF-kappaB, all-trans-Retinoic Acid, SP1, Ras, 
TGF-beta1 among many others. 
Localisation 
HAS2 is localized in the plasma membrane as a 
multipass transmembrane protein. Although it has been 
suggested the human HAS2 may share the same 
proposed topological domains as its bacterial 
counterpart, the extent to which this statement trully 
represents its actual architecture has not yet been 
shown. 
Function 
Hyaluronan synthase 2 is responsible for the synthesis 
and deposition of hyaluronan in the extracellular 
matrix. HAS2 is a member of the glycosyl transferas 2 
protein family and catalyses the addition of UDP-
esterified residues, to form  
glucuronic acid and N-acetylglucosamine dissacha-ride 
motifs present in HA molecules. Interactions between 
plasma membrane embedded HA receptors with 
hyaluronan in the cellular matrix have been suggested 
to either induce or repress HAS2's catalytic activity. 
The presence of hyaluronan in the extracellular matrix 
has been linked to a great number of vital cellular 
processes such cell division, motility and 
morphogenesis, among many others. HAS2 is either an 
oncogene or a tumor suppressor depending on the 
concentration and length of HA products deposited in 
the extracellular matrix. Long HA chains of high 
molecular weight in high concentrations have been 
linked with supressing angiogenesis and tumor 
proliferation, whereas 2-3 fold HAS2 overexpression 
has been implicated in the proliferation and metastasi  
in various genitourinary tumor types. 
Homology 
A total of 3 mammalian HAS genes have been isolated 
and identified (HAS1, HAS2, HAS3). Although they 
share similar amino acid sequences and structural 
conformations, each isozyme present different spacial 
and temporal expression patterns, molecular stability, 
kinetic properties and ability of yielding hyaluronan 
chains different in length and concentration. 
Mutations 
Note 
Developmental studies have described mutations 
disrupting HAS2 synthesis as embryonic lethal. Such 
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Studies dating over 50 years have suggested an 
association between the increasing deposition of HA 
and tumors. Because hyaluronan is associated with 
such a variety of important biological cellular 
processes, it has been suggested that the abnormal 
overexpression of HAS2, among the other HA 
synthases, as well as deposition of HA in the 
extracellular matrix account for hijacked pathways to 
stimulate cell growth, proliferation, angiogenesis and 
metastasis in cancer cells. The use of pharmacological 
agents affecting HAS2 activity, as well as, HA 
breakdown in cancer treatment are promising. Recent 
studies suggest that tumor cells become less aggressive 
and proliferative when HA synthase is being 
suppressed or overexpressed in high concentrations. 
Diagnostic tests have been developed assaying for 
concentration of deposited hyaluronan as a tumor 
marker. The HA-Hase test, for example, is a sensitive 
and accurate diagnostic test for bladder cancer 
measuring the concentrations of hyaluronan and 
hyaluronidase (HA degrading protein) present in urine 
samples. 
Disease 
Dysfunctional expression of HAS2 has been published 
in many genitourinary tumors, such as prostate cancer, 
testicular cancer and bladder cancer. This altered 
expression has been linked with chromosomal locus 
8q24 amplification as well as deregulated HAS2 
transcription, which have been shown to follow tumor 
progression. 
Prognosis 
Histological studies, using specific hyaluronan affinity 
probes, suggest that all human epithelial tumors are 
associated with elevated amounts of hyaluronan in the 
extracellular matrix. Consequen-tly, overexpression of 
HAS2 has been observed in various types of cancer. 
The presence of tumor associated hyaluronan has been 
observed in prostate cancer cells of high Gleason sc re  
and matastasis, indicating poor prognosis. Also, 
primary tumor invasiveness and elevated PSA 
recurrence after surgical tumor removal have been 
correlated with strong stromal hyaluronan staining i  
radical prostatectomy specimens. 
Vascular disease 
Disease 
Changes in the concentration and cellular distribu-t on 
of HA have been observed in vascular diseases such as 
atherosclerosis, restenotic lesion. 
Prognosis 
Increasing severity in athrosclerosis has been linked 
with decreasing concentration of hyaluronan 
distribution. Yet, the role HA may be playing during 
earlier phases of the disease is yet to be determind due 
to difficulty in early detection of the disease. Decreased 
HAS2 activity is stipulated to be playing a possible role 
in this matter. 
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